



**Weill Cornell
Medicine-Qatar**
Continuing Professional
Development

Protein Misfolding Diseases and Neurodegeneration: From Experimental Approach to Clinical Therapy Series

October 5, 2022 - October 25, 2023
Online via Zoom

Course Director

Ali Chaari, PhD

*Assistant Professor of Biology
Weill Cornell Medicine-Qatar*

Overall Objectives:

At the end of this activity, participants will:

- 1 Identify the risk factors and patterns of onset of neurodegenerative diseases
- 2 Demonstrate an understanding of the mechanisms of the development of the most common neurodegenerative diseases
- 3 List the latest developments in the field of diagnosis and treatment of neurodegenerative diseases
- 4 Recognize the emerged importance of artificial intelligence in neurodegenerative diseases diagnosis
- 5 Recognize the associations between physical activity, sleep and cognitive function in older adults

Target Audience:

Physicians, Dentists, Allied Health Practitioners, Nurses, Pharmacists, Students, Researchers, Educators



SCAN ME



DHP Credit Designation Statement:

This activity is an Accredited Group Learning Activity (Category 1) as defined by the Ministry of Public Health's Department of Healthcare Professions-Accreditation Section and is approved for a maximum of 1.25 hours.

The scientific planning committee has reviewed all disclosed financial relationships of speakers, moderators, facilitators and/or authors in advance of this CPD activity and has implemented procedures to manage any potential or real conflicts of interest.



ACCME Credit Designation Statement:

The Weill Cornell Medicine-Qatar designates this live activity for a maximum of 1.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



Program

Online via Zoom
October 2022 - October 2023

Protein Misfolding Diseases and Neurodegeneration: From Experimental Approach to Clinical Therapy Series

Agenda

Date/Time	Topic	Session Learning Objectives	Speaker
October 5, 2022 5:00 pm – 6:15 pm (Including Q&A: 5:50 - 6:15 pm)	The Molecular Basis of Neurodegenerative Diseases: From Bench to Bedside	<ul style="list-style-type: none"> Discuss the role of protein aggregation in neurodegeneration Identify molecular alterations in synucleinopathies Define the targets for therapeutic intervention in neurodegenerative diseases 	Dr. Tiago Outeiro
October 19, 2022 5:00 pm – 6:15 pm (Including Q&A: 5:50 - 6:15 pm)	Disease Modification in Parkinson Disease: An Update	<ul style="list-style-type: none"> Discuss the mechanisms of neurodegeneration in Parkinson disease and the role of genes and environment Identify the biological, imaging and clinical biomarkers Outline the current status of disease modifying studies 	Dr. Angelo Antonini
January 18, 2023 11.30 am – 12:45 pm (Including Q&A: 12:20 - 12:45 pm)	Late Onset (Sporadic) Alzheimer's Disease: Caused by Defective Innate Immunity and Treated with Adaptive Immunity	<ul style="list-style-type: none"> Discuss where and when does AD start. Explain if the default mode network, synaptic plasticity, and the normal function of APP involved in ADE Explain the molecular species of Aβ cause synaptic degeneration Explain if the impaired innate immunity is responsible for failure of Aβ clearance Outline the biomarker cut points of normality vs the preclinical, prodromal, and clinical stages of AD Define the best disease modifying therapeutic strategies for AD 	Dr. Colin Masters
February 22, 2023 11.30 am – 12:45 pm (Including Q&A: 12:20 - 12:45 pm)	How Lifestyle Shapes the Brain: Associations between Physical Activity, Sleep, Beta-amyloid and Cognitive Function in Older Adults	<ul style="list-style-type: none"> Discuss the associations between physical activity, sleep and cognitive function in older adults 	Dr. Hamid Sohrabi
March 22, 2023 5:00 pm – 6:15 pm (Including Q&A: 5:50 - 6:15 pm)	Genetic Synucleinopathies: A Window to Idiopathic Parkinson's Disease?	<ul style="list-style-type: none"> Discuss the types of genetic synucleinopathies. Discuss the clinical picture of genetic synucleinopathies Discuss the biomarker profile of PD patients with genetic synucleinopathies Discuss the imaging profile of genetic synucleinopathies Discuss similarities and differences between genetic synucleinopathies and iPD 	Dr. Leonidas Stefanis
April 12, 2023 2:00 pm – 3:15 pm (Including Q&A: 2:50 - 3:15 pm)	The Parkinson Disease: A Local Prospective	<ul style="list-style-type: none"> Define the key terminologies related to movement disorders Compare hyperkinetic Vs hypokinetic disorders Discuss the etiology and risk factors causing Parkinson's disease Explain the clinical features, investigations, differential diagnosis and management of Parkinson's disease 	Dr. Gholam Redha Adeli
May 24, 2023 5:00 pm – 6:15 pm (Including Q&A: 5:50 - 6:15 pm)	Intrinsically Disordered Proteins in Human Diseases	<ul style="list-style-type: none"> Explain how the intrinsically disordered proteins have specific features and are predictable Explain how intrinsic disorder is highly abundant in various proteomes especially in their signaling proteins Explain how intrinsically disordered proteins have specific functions and are tightly controlled in the norm Explain how dysregulation of these proteins often leads to various diseases and explain how many disease-related proteins are disordered Explain how disordered proteins represent attractive but challenging drug targets 	Dr. Vladimir Uversky
June 21, 2023 5:00 pm – 6:15 pm (Including Q&A: 5:50 - 6:15 pm)	Current State of Biomarkers for the Early Detection of Alzheimer's Disease	<ul style="list-style-type: none"> Recognize and list the latest developments in the field of diagnosis and treatment of neurodegenerative diseases Recognize the current state of biomarkers for the early detection of Alzheimer's disease 	Dr. Michael Schöll
September 20, 2023 5:00 pm – 6:15 pm (Including Q&A: 5:50 - 6:15 pm)	Why Do Clinical Trials for Neurodegenerative Diseases Keep Failing?	<ul style="list-style-type: none"> Explain the FDA position on end points in clinical trials of neurodegenerative diseases Identify the need for better end-points in clinical trials of neurodegenerative diseases Use examples in diabetic neuropathy and dementia of failed trials Identify corneal confocal microscopy as a novel end-point in clinical studies of neurodegenerative disease 	Dr. Rayaz Ahmed Malik
October 25, 2023 5:00 pm – 6:15 pm	Cornell Neurodegenerative Disease: From Bench to Bedside Panel Discussion (Including Q&A)	TBC	Drs. Ali Chaari, Tiago Outeiro, Rayaz Ahmed Malik, Vladimir Uversky, Angelo Antonini and Michael Schöll